A microdose is a deliberately low dose of tirzepatide — below the maximum dosing used in standard weight-loss protocols. The idea is the smallest effective amount: enough to gently take the edge off appetite and cravings, with a gentler overall experience. It's a popular approach for people easing into GLP-1s, maintaining progress, or simply preferring a lighter touch. Your provider determines the appropriate dose for you based on your goals and history.

Eating less can leave energy lower, and fatigue is one of the most common complaints people have on a GLP-1. Vitamin B12 is an essential nutrient central to turning food into usable energy and forming healthy red blood cells, so it's paired with the microdose to help support your energy and vitality while your appetite settles. The goal is balance — gentle appetite support without feeling wiped out.

Tirzepatide is the active ingredient found in some well-known branded dual-agonist medications. What's offered through ILSA is a compounded, low-dose tirzepatide paired with B12 — prepared by a licensed U.S.-based pharmacy when a provider authorizes treatment. It is not a branded product and is offered cash-pay. It's the same dual GLP-1/GIP class, used here at a microdose; your provider can explain the specifics for your situation.

Both are gentle, low-dose options paired with B12. The difference is the molecule: semaglutide acts on a single hormone receptor (GLP-1), while tirzepatide is a dual agonist that acts on both GLP-1 and GIP. Tirzepatide is generally regarded as the more powerful molecule, so a microdose of it offers that dual-action reach in a gentler form. Which is the better fit depends on your history, goals, and tolerance — a conversation for your provider, not a one-size-fits-all answer.

Yes. Tirzepatide is a prescription medication, even at a microdose. ILSA is a telehealth platform — it doesn't prescribe. Instead, ILSA connects you with independent, licensed providers who review your secure online intake and health history and determine whether it's appropriate for you. If it isn't a good fit, they'll tell you. The clinical decision always rests with the provider.

Tirzepatide is a dual GIP and GLP-1 receptor agonist — it mimics two of the gut hormones released after eating. It slows how quickly your stomach empties (so you feel full longer) and acts on the brain's appetite centers (so you feel less hungry, with fewer cravings). At a microdose, that dual effect is gentler. The added B12 supports your energy. Most people don't describe it as forcing themselves to eat less — they describe simply wanting a bit less, without feeling drained.

Maybe — but it's important to be honest: a microdose is a gentler approach, and any weight effect is generally more modest than the maximum weight-loss dosing. In clinical studies, tirzepatide alongside diet and exercise helped adults lose a meaningful share of body weight, but those studies used higher doses. Many people choose a microdose for gentle support, maintenance, or wellness rather than dramatic loss. Results vary, it works best with healthy eating and movement, and your provider will set realistic expectations for you.

Like any medication, tirzepatide can have side effects — most commonly gastrointestinal ones such as nausea. A key reason people choose a microdose is that a lower dose is generally gentler and better tolerated, which can mean a smoother adjustment. They're not eliminated, though, and everyone responds differently. Your provider reviews your history, explains what to watch for, and is available if anything comes up. Always report concerning symptoms promptly.

Tirzepatide isn't right for everyone. It is generally not appropriate for people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, those who are pregnant or breastfeeding, and certain other conditions. This is exactly why a provider review is required: your individual history determines eligibility. Be complete and honest in your intake so the provider can make a safe decision.

Yes — tirzepatide is a small subcutaneous injection, typically once a week, using a fine needle. Your kit ships with the supplies you need, and the platform provides clear guidance on how to do it comfortably at home. Most people find it quick and far less daunting than they expected. If self-injecting concerns you, mention it in your intake so your provider can walk you through it.

Tirzepatide is available nationwide through the ILSA platform, subject to provider evaluation, eligibility, and the rules of your state. Whether treatment can be authorized depends on your individual review and where you live. The fastest way to find out is to start the online visit — there's no commitment until a provider approves.

Once a provider authorizes treatment, a licensed U.S.-based pharmacy prepares your tirzepatide and ships it cold-packed and discreetly to your door. It typically needs refrigeration, and your kit includes storage and handling instructions. If anything about a shipment looks off, reach out through the ILSA platform before using it.

The formula and provider oversight are identical — the difference is supply length and price per month. The 1-month plan ($249) is the simplest way to ease in and see how you respond. The 3-month plan ($499) is the best value, dropping the effective cost to about $166.33/month. Both are cash-pay with no insurance required and no hidden fees. Many people start with one month and extend once they've settled into the routine.

Yes. Your intake and health information are handled through HIPAA-compliant systems. Your data is used to connect you with a provider and fulfill an authorized order — not sold. You stay in control of your information throughout.